Laboratoire X.O, backed by European mid-market private equity firm Stanley Capital Partners, announced on November 6 that it purchased nimodipine from Bayer AG, a German biopharmaceutical company.
nimodipine is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage. nimodipine is sold and marketed under the brand name Nimotop.
Laboratoire X.O is a pharmaceutical company that specializes in mature market authorizations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care and women’s health. It is based in Paris, France.
The deal covers the sale of nimodipine in several markets around the world, but not China. Financial terms of the acquisition were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 91st Pharmaceuticals transaction of the year. This is a slight increase from the year before when 83 Pharmaceuticals acquisitions were reported between January 1, 2022, and November 6, 2022.
Additionally, Bayer has completed two acquisitions during 2023. In January, the company purchased Blackford Analysis Ltd, which provides software products that accelerate the comparison of medical images, for an undisclosed price. Then, in June, it bought a cyclin-dependent kinase 2 inhibitor from Cedilla Therapeutics.
